Physiotens pills 0.4mg, 28pcs

Composition

of 1 tab. moxonidine 0.4 mg

Auxiliary substances:

lactose monohydrate – 95.6 mg,

povidone-0.7 mg,

crospovidone-3 mg,

magnesium stearate-0.3 mg.

Shell composition:

hypromellose-1.3 mg,

ethylcellulose-1.2 mg,

macrogol-0.25 mg,

talc-0.875 mg,

iron oxide red dye (E 172) – 0.125 mg,

titanium dioxide (E 171) – 1.25 mg

Pharmacological action

Antihypertensive agent. The mechanism of action of moxonidine is mainly associated with its effect on the central links of blood pressure regulation. Moxonidine is an agonist of mainly imidazoline receptors.

By stimulating these receptors of neurons in the solitary tract, moxonidine, through the system of inhibitory interneurons, helps to inhibit the activity of the vasomotor center and thus reduce the descending sympathetic effects on the cardiovascular system. Blood pressure (systolic and diastolic) decreases gradually.

Moxonidine differs from other sympatholytic antihypertensive agents by a lower affinity for_α2-adrenergic receptors, which explains the lower probability of developing sedation and dry mouth.

Moxonidine increases the insulin sensitivity index (compared to placebo) by 21% in patients with obesity, insulin resistance, and moderate arterial hypertension.

Indications

Arterial hypertension.

Contraindications

Severe bradycardia (less than 50 beats / min), SSR, grade II and III AV block, acute and chronic heart failure, lactation (breastfeeding), children and adolescents under 18 years of age, hypersensitivity to moxonidine.

Side effects

From the central nervous system:  often – headache, dizziness (vertigo), drowsiness; infrequently-fainting.

From the cardiovascular system:  infrequently – marked decrease in blood pressure, orthostatic hypotension, bradycardia.

From the digestive system:  very often-dry mouth; often-diarrhea, nausea, vomiting, dyspepsia.

Skin and subcutaneous tissue disorders:  often – skin rash, pruritus; infrequently-angioedema.

From the side of the psyche:  often – insomnia; infrequently-nervousness.

Hearing disorders and labyrinth disorders:  infrequently-ringing in the ears.

Musculoskeletal disorders:  often-back pain; infrequently-neck pain.

From the body as a whole:  often-asthenia; infrequently-peripheral edema.

Interaction

The combined use of moxonidine with other antihypertensive agents leads to an additive effect.

Tricyclic antidepressants can reduce the effectiveness of central antihypertensive agents, so they are not recommended to be taken together with moxonidine.

Moxonidine may enhance the effects of tricyclic antidepressants, tranquilizers, ethanol, sedatives, and sleeping pills.

Moxonidine is able to moderately improve impaired cognitive function in patients receiving lorazepam.

Moxonidine may increase the sedative effect of benzodiazepine derivatives when administered concomitantly.

Moxonidine is secreted by tubular secretion. Therefore, its interaction with other drugs released by tubular secretion is not excluded.

How to take, course of use and dosage

They are taken orally. The initial dose is on average 200 mcg orally 1 time/day. The maximum single dose is 400 mcg. Individual adjustment of the daily dose is necessary, depending on the tolerability of therapy. The maximum daily dose is 600 mcg in 2 divided doses.

For patients with moderate and severe renal insufficiency, as well as those on hemodialysis, the initial dose is 200 mcg / day. If necessary and with good tolerability, the daily dose can be increased to a maximum of 400 mcg.

Special instructions

Special care should be taken when using moxonidine in patients with grade I AV block (risk of developing bradycardia); severe coronary vascular disease and unstable angina (insufficient experience); and renal insufficiency.

If it is necessary to cancel simultaneously taken beta-blockers and moxonidine, first cancel beta-blockers and only after a few days – moxonidine.

Currently, there is no evidence that discontinuation of moxonidine leads to an increase in blood pressure. However, it is not recommended to abruptly stop taking moxonidine, the dose should be reduced gradually, over 2 weeks.

Influence on the ability to drive motor vehicles and manage mechanisms

During treatment, patients should exercise caution when engaging in potentially dangerous activities that require concentration of attention and a high rate of psychomotor reactions.

Active ingredient

Moxonidine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For pregnant women as prescribed by a doctor, For adults as prescribed by a doctor

Indications

Hypertension